Vascular Diseases
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Second, we tested whether loss-of-function mutations in APOC3, which were associated with reduced levels of nonfasting triglycerides, were also associated with reduced risks of ischemic vascular disease and ischemic heart disease.
|
24941082 |
2014 |
Vascular Diseases
|
0.020 |
GeneticVariation
|
group |
BEFREE |
In humans, loss-of-function mutations in APOC3 are associated with reduced plasma TG levels and reduced risk for ischemic vascular disease and coronary heart disease.
|
26435212 |
2015 |
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The present study aimed to investigate the value of apolipoproteins, including ApoA-1, ApoC-III, and ApoE, in patients with small cell lung cancer (SCLC) as potential biomarkers for diagnosis, prognosis, and cancer progression.
|
26996551 |
2016 |
Triglycerides measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
23063622 |
2012 |
Triglycerides measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Whole genome sequencing and imputation in isolated populations identify genetic associations with medically-relevant complex traits.
|
28548082 |
2017 |
Triglycerides measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Very low-depth whole-genome sequencing in complex trait association studies.
|
30576415 |
2019 |
Thin-cap fibroatheroma
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These indexes were independent predictors of the presence of TCFA (ΔApoB-48: odds ratio, 1.608; 95% confidence interval, 1.040-2.486; P=0.032; apolipoprotein C-III: odds ratio, 2.581; 95% confidence interval, 1.177-5.661; P=0.018).
|
29930008 |
2018 |
Thanatophoric dysplasia, type 2
|
0.010 |
Biomarker
|
disease |
BEFREE |
We sequenced APOC3 3'UTR in 100 type 2 diabetic (TD2) patients with severe HTG (TG > 15 mmol/L) (HTG group) compared to 100 normotriglyceridemic patients (NTG group).
|
27794214 |
2016 |
Syphilis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Biomarker analysis revealed three proteins (Apo-A1, Apo-CIII, CRP) that differed between syphilis and other causes.
|
31697216 |
2019 |
Steatohepatitis
|
0.080 |
Biomarker
|
disease |
BEFREE |
The impact of the APOC3 SNPs on fatty liver is small and depends on visceral obesity.
|
21829161 |
2012 |
Steatohepatitis
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3, but not the APOC3 rs2854116 SNP, was associated with fatty liver but not with triglyceride levels.
|
22105854 |
2012 |
Steatohepatitis
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
By multivariable Cox analysis, concurrent fatty liver (HR 7.27, 95% confidence interval: 1.52-34.76; P = 0.013), age, cirrhosis, and APOC3 rs2854116 TC/CC genotype (HR 3.93, 95% confidence interval: 1.30-11.84; P = 0.013) were independent factors predicting HCC development.
|
27547913 |
2017 |
Steatohepatitis
|
0.080 |
Biomarker
|
disease |
BEFREE |
APOC3 neither exacerbated diet-induced adiposity nor aggravated the degree of steatosis in high fructose or high fat-fed APOC3-transgenic mice.
|
28115523 |
2017 |
Steatohepatitis
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
However, APOC3 SNPs, alone or in combination, were not associated with insulin resistance, altered lipid levels, liver enzymes, and with liver damage (severity of steatosis, nonalcoholic steatohepatitis, and moderate/severe fibrosis) in Italian as well as in UK patients, and in the whole cohort.
|
21777557 |
2011 |
Steatohepatitis
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
APOC3 polymorphisms had no effect on the development of steatosis and no influence on the PNPLA3 polymorphism.
|
23808989 |
2013 |
Steatohepatitis
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
The APOC3 rs2070666 A allele was linked to the fourth quartile of the controlled attenuation parameter values (OR 2.769, 95 % CI 1.002-7.651) in 131 subjects, and also linked to the significant histological steatosis (OR 4.986, 95 % CI 1.020-24.371), but neither to liver stiffness measurement values nor to hepatic histological activity and fibrosis in NAFLD patients.
|
27059980 |
2016 |
Steatohepatitis
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans.
|
21663607 |
2011 |
Spinocerebellar Ataxia 12
|
0.010 |
Biomarker
|
disease |
BEFREE |
Altered expression of some of the proteins of interest, transthyretin, haptaglobin, apolipoprotein C-II, apolipoprotein C-III are indicative of clinical manifestations such as neuropathy, cognitive impairment and altered lipid metabolism in SCA12.
|
22426495 |
2012 |
Small cell carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
ApoA-1 and ApoC-III may be used as differentiating and predictive markers for SCLC.
|
26996551 |
2016 |
Serum total cholesterol measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
23063622 |
2012 |
Serum albumin measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association study identifies multiple loci influencing human serum metabolite levels.
|
22286219 |
2012 |
Retinal Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The apoCIII concentration also was significantly higher in the group of patients with severe retinopathy (ETDRS 10-23) compared to those with moderate (ETDRS 4-9; P<.02) or mild retinopathy (ETDRS 1-3; P<.0001).
|
15642486 |
2005 |
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
To examine cancer-related allelic loss in the region between D11S940 and APOC3, we used 17 polymorphic markers and allotyped 28 lung cancer-derived cell lines and their corresponding matched lymphoblastoid cell lines.
|
10337999 |
1999 |
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Expression profiles of ApoA-1, ApoC-III, and ApoE in different samples were examined using immunohistochemical methods, and the expression levels were correlated with cancer types, treatment, and outcomes using chi-square and Mann-Whitney tests.
|
26996551 |
2016 |
Primary malignant neoplasm
|
0.030 |
GeneticVariation
|
group |
BEFREE |
apoC-III associated with apoB, apoAI, and Lp(a) (apoCIII-apoB, apoCIII-apoAI, and apoCIII-Lp(a), respectively) were measured using high-throughput chemiluminescent enzyme-linked immunoassays in 2711 subjects (1879 controls and 832 cases with CAD) in the European Prospective Investigation into Cancer and Nutrition-Norfolk prospective population study with 7.4 years of follow-up.
|
30249512 |
2019 |